Will last year's buybacks morph into more M&A for 2012?

After spending last year focusing on billion-dollar share buybacks to shore up their stock and please investors, European pharma companies may focus more on dealmaking this year, analysts say. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.